UBS’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$842K Buy
16,200
+11,400
+238% +$581K ﹤0.01% 3768
2014
Q2
$246K Buy
4,800
+1,500
+45% +$67.6K ﹤0.01% 4935
2014
Q1
$157K Buy
3,300
+600
+22% +$30.7K ﹤0.01% 5471
2013
Q4
$117K Buy
2,700
+1,800
+200% +$74.5K ﹤0.01% 5889
2013
Q3
$39K Buy
900
+300
+50% +$12.2K ﹤0.01% 7185
2013
Q2
$21K Buy
+600
New +$21.1K ﹤0.01% 7841

Other funds holding XBI

UBS's XBI Position: Q3 2014 in Review

UBS increased its State Street SPDR S&P Biotech ETF (XBI) stake by 6.6% in Q3 2014, buying an estimated $4.6M and bringing the position to 1,455,717 shares worth $75.7M. The position accounts for 0.06% of the portfolio, ranked #342.

UBS first reported a position in XBI in Q2 2013 and has held it in 6 quarters since. 129 funds tracked by Wall St. Rank hold XBI as of Q3 2014.

  • UBS held 1,455,717 shares of State Street SPDR S&P Biotech ETF worth $75.7M as of Q3 2014.
  • UBS bought 90,201 State Street SPDR S&P Biotech ETF shares in Q3 2014, an estimated $4.6M.
  • State Street SPDR S&P Biotech ETF made up 0.06% of UBS's portfolio in Q3 2014, its #342 holding.
  • UBS first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 6 quarters since.
  • 129 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.